Next Article in Journal
Class A Scavenger Receptors Are Used by Frog Virus 3 During Its Cellular Entry
Previous Article in Journal
Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Viruses 2019, 11(2), 92; https://doi.org/10.3390/v11020092

Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters

1
Department of Animal, Dairy, and Veterinary Sciences, Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA
2
Institute for Antiviral Research, and Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA
3
Department of Pathology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450066, China
4
Utah Veterinary Diagnostics Laboratory, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA
5
SAB Biotherapeutics, Sioux Falls, SD 57104, USA
6
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
7
Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E, Canada
*
Authors to whom correspondence should be addressed.
Received: 2 December 2018 / Revised: 18 January 2019 / Accepted: 19 January 2019 / Published: 22 January 2019
(This article belongs to the Section Antivirals & Vaccines)
Full-Text   |   PDF [4510 KB, uploaded 22 January 2019]   |  

Abstract

Zika virus (ZIKV) infection can cause severe congenital diseases, such as microcephaly, ocular defects and arthrogryposis in fetuses, and Guillain–Barré syndrome in adults. Efficacious therapeutic treatments for infected patients, as well as prophylactic treatments to prevent new infections are needed for combating ZIKV infection. Here, we report that ZIKV-specific human polyclonal antibodies (SAB-155), elicited in transchromosomal bovine (TcB), provide significant protection from infection by ZIKV in STAT2 knockout (KO) golden Syrian hamsters both prophylactically and therapeutically. These antibodies also prevent testicular lesions in this hamster model. Our data indicate that antibody-mediated immunotherapy is effective in treating ZIKV infection. Because suitable quantities of highly potent human polyclonal antibodies can be quickly produced from the TcB system against ZIKV and have demonstrated therapeutic efficacy in a small animal model, they have the potential as an effective countermeasure against ZIKV infection. View Full-Text
Keywords: STAT2 KO hamster; transchromosomal bovine antibody; Zika virus; therapeutic; testis STAT2 KO hamster; transchromosomal bovine antibody; Zika virus; therapeutic; testis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Siddharthan, V.; Miao, J.; Van Wettere, A.J.; Li, R.; Wu, H.; Sullivan, E.; Jiao, J.; Hooper, J.W.; Safronetz, D.; Morrey, J.D.; Julander, J.G.; Wang, Z. Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters. Viruses 2019, 11, 92.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top